WilmerHale Counsels Tokai Pharmaceuticals in Share Purchase Agreement with Otic Pharma

WilmerHale Counsels Tokai Pharmaceuticals in Share Purchase Agreement with Otic Pharma

Firm News

Tokai Pharmaceuticals Inc. and Otic Pharma Ltd., a privately held, clinical-stage pharmaceutical company focusing on the development and commercialization of products for disorders of the ear, nose and throat, announced that the two companies—together with the shareholders of Otic Pharma—have entered into a definitive share purchase agreement under which the shareholders of Otic Pharma will become the majority owners of Tokai.

The WilmerHale deal team included Partners Hal Leibowitz, Stuart Falber, Belinda Juran, Bill Caporizzo and Amy Null; Counsel Michael Welhouse; Senior Associate Ryan Mitteness; and Associate Andrea Sorrentino.

Read Tokai Pharmaceuticals' press release for more information.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.